Published and Forthcoming Papers
The Market for High Quality Medicine: Retail Chain Entry and Drug Quality in India (2019) (w/ Dan Bennett), Review of Economics Statistics 101:1, March 2019 [Appendix]
Insurers’ Negotiating Leverage and the External Effect of Medicare Part D (with Darius Lakdawalla), Review of Economics and Statistics, 97:2 p.314-331 May 2015 (an earlier version appears as NBER working paper no. 16251)
R&D Policy, Agency Costs and Innovation in Personalized Medicine, Journal of Health Economics, September 2009, 28(5), pp. 950-962
Market Incentives and Pharmaceutical Innovation, Journal of Health Economics, July 2008, 27(4), pp. 1060-1077
Female Empowerment: Impact of a Commitment Savings Product in the Philippines (with Nava Ashraf and Dean Karlan) World Development, 2010, 38(3), pages 333-344
Tying Odysseus to the Mast: Evidence from a Commitment Savings Product in the Philippines (with Nava Ashraf and Dean Karlan) Quarterly Journal of Economics, May 2006, 121(2). Winner of TIAA-CREF 2006 Certificate of Excellence
Designing Targeting Schemes with Poverty Maps: Does Disaggregation Help? (with Berk Özler, Chris Elbers, Tomoki Fujii, Peter Lanjouw), Journal of Development Economics, May 2007, 83(1)
Deposit Collectors (with Nava Ashraf and Dean Karlan), Advances in Economic Analysis & Policy, March 2006, 6(2), Article 5
Published Policy and Medical Journal Articles
Value of Survival Gains in Chronic Myeloid Leukemia (withJohn Penrod, J. Ross Maclean, Darius Lakdawalla and Tomas Philipson) American Journal of Managed Care2012 Nov;18(11 Suppl):S257-64
The impact of Medicare Part D on Medicare-Medicaid Dual-eligible Beneficiaries' Prescription Utilization and Expenditures (with Caleb Alexander and Anirban Basu), Health Services Research, February 2010, 45(1), pp. 133-151
Valuing health technologies at NICE: Recommendations for Improved Incorporation of Treatment Value in HTA (with Dana Goldman, Darius Lakdawalla and Tomas Philipson) Health Economics October 2010, 10(11) pp. 1109-1116The
Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures (with Anirban Basu, James Zhang, Atonu Rabbani, David Meltzer, Caleb Alexander) Annals of Internal Medicine, Lead article, February 2008, 148:3 pp. 169-177
Solutions and Challenges to Curing Global Health Inequality Innovations 2(4), October 2007, 2(4), pp. 72-80Impact of the Medicare Part D prescription benefit on use of generic drugs and different therapeutic drug classes (with James Zhang and Caleb Alexander) The Journal of General Internal Medicine, October 2008, 23:10 pp. 1673-1678
Testing Savings Product Innovations Using an Experimental Methodology (with Nava Ashraf and Dean Karlan), Asian Development Bank, Economics and Research Department Technical Paper No. 8. November, 2003
A Review of Commitment Savings Products in Developing Countries (with Nava Ashraf, Nathalie Gons and Dean Karlan), Asian Development Bank, Economics and Research Department Working Paper No. 45 June, 2003
“How retail drug markets in poor countries develop” (with Dan Bennett) VoxDev.org, August, 13th, 2018.
“Potential Impacts of Graham-Cassidy-Heller-Johnson on Californians and the Individual Health Insurance Market” Covered California Report, September 25, 2017 (w/ John Berko)
“Evaluating the Potential Consequences of Terminating Direct Federal Cost-Sharing Reduction (CSR) Funding” Covered California Report, January 26, 2017 (w/Richard Domurat)
“Trump’s “populist” economic proposals come with massive catches. Here's what to watch for.” Vox, November 18, 201
“
Strengthening Risk Protection through Private Long-Term Care Insurance” Brookings Institution, Hamilton Project
